Proton therapy technology company ProTom International Holding Corporation reported on Monday the receipt of the 510(k) clearance from the US Food and Drug Administration (FDA) for its Radiance 330 proton therapy system.
Installed at Massachusetts General Hospital (MGH) in Boston, Massachusetts, the company's Radiance 330 proton therapy system is a compact, single room system equipped with an advanced pencil beam scanning system and integrated imaging and control system.
By using the advanced pencil beam scanning technology, modular designed treatment system and the compact synchrotron particle accelerator, the company's Radiance 330 is a smaller, lighter and cleaner system. The Radiance 330 compact synchrotron can be installed within an interior accelerator vault space of 20′ x 30′ and requires up to 40% less radiation shielding.
Mass General Hospital is the original and the largest teaching hospital of Harvard Medical School located in Boston, Massachusetts.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT